X4 Pharmaceuticals, Inc.
XFOR
NASDAQ·Healthcare·Biotechnology·Mkt cap $381.1M
$4.04
▲ 0.00%
P/E
-3.37
Mkt Cap
$381.1M
52-Wk Range
$2.80–$4.83
52-Week Range
$2.80 - $4.83
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 19.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+8.9% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying XFOR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of -$0.13 vs -$0.18 consensus (+26.1% surprise). Revenue of $8.8M vs $2.4M expected (+263.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+26.1%
Revenue trend · last 8Q
—
—
—
—
+215%
+79%
-91%
+346%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$560.0K
$1.4M
$28.8M
$2.0M
$1.8M
$2.6M
$2.7M
$8.8M
Margins · last 8Q
Gross
81.6%
Operating
-186.1%
Profit
-183.5%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wells Fargo · Jul 10, 2026
vs Industry
How XFOR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.